Cancer Letters
Volume 230, Issue 1 , Pages 33-46, 8 December 2005

Cooperative cell-growth inhibition by combination treatment with ZD1839 (Iressa) and trastuzumab (Herceptin) in non-small-cell lung cancer☆

  • Hisashi Nakamura

      Affiliations

    • Department of Surgery, Kurume University School of Medicine, 67 Asahi-Machi, Kurume 830-0011, Japan
    • Research Center for Innovative Cancer Therapy of the 21st Century COE Program for Medical Science, Kurume University School of Medicine, Kurume 830-0011, Japan
    • ,
  • Shinzo Takamori

      Affiliations

    • Department of Surgery, Kurume University School of Medicine, 67 Asahi-Machi, Kurume 830-0011, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 942 31 7566; fax: +81 942 34 0709.
    • ,
  • Teruhiko Fujii

      Affiliations

    • Research Center for Innovative Cancer Therapy of the 21st Century COE Program for Medical Science, Kurume University School of Medicine, Kurume 830-0011, Japan
    • ,
  • Mayumi Ono

      Affiliations

    • Department of Medical Biochemistry, Graduate School of Medical Sciences, Kyushu University School of Medicine, Fukuoka 812-8582, Japan
    • ,
  • Hideaki Yamana

      Affiliations

    • Research Center for Innovative Cancer Therapy of the 21st Century COE Program for Medical Science, Kurume University School of Medicine, Kurume 830-0011, Japan
    • ,
  • Michihiko Kuwano

      Affiliations

    • Research Center for Innovative Cancer Therapy of the 21st Century COE Program for Medical Science, Kurume University School of Medicine, Kurume 830-0011, Japan
    • ,
  • Kazuo Shirouzu

      Affiliations

    • Department of Surgery, Kurume University School of Medicine, 67 Asahi-Machi, Kurume 830-0011, Japan

Received 21 September 2004; received in revised form 26 November 2004; accepted 15 December 2004.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ Iressa is a trademark of the AstraZeneca group of companies.

PII: S0304-3835(04)00995-4

doi:10.1016/j.canlet.2004.12.020

Cancer Letters
Volume 230, Issue 1 , Pages 33-46, 8 December 2005

Article Tools

* Image Usage & Resolution